Skip to main content

Table 3 Activity Sorafenib and Sunitynib in ChRCC

From: Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease

Agent No. of patients Median PFS (months) Partial Response
No. of patients
Stable Disease
No. of patients
Sunitinib 7 8.9 1 6
Sorafenib 5 27.5 2 3
\